UPLOAD Filing
Indaptus Therapeutics, Inc.
Date: Aug. 18, 2025 · CIK: 0001857044 · Accession: 0000000000-25-008684
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289576
Letter
Re: Indaptus Therapeutics, Inc. Registration Statement on Form S-3 Filed August 13, 2025 File No. 333-289576 Dear Jeffrey Meckler:
August 18, 2025
Jeffrey Meckler Chief Executive Officer Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, NY 10019
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Gary Emmanuel, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> August 18, 2025 Jeffrey Meckler Chief Executive Officer Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, NY 10019 Re: Indaptus Therapeutics, Inc. Registration Statement on Form S-3 Filed August 13, 2025 File No. 333-289576 Dear Jeffrey Meckler: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Gary Emmanuel, Esq. </TEXT> </DOCUMENT>